April 05-08, 2021
FUJIFILM Diosynth Biotechnologies is delighted to be presenting at BPI Asia virtual conference, April 5-8, 2021.
Please Join Us:
April 5, 2021, at 9:30am JST
Fay Saunder, Head of the Mammalian Cell Culture (MCC) PD team at FUJIFILM Diosynth Biotechnologies, UK will be presenting on Apollo™X: Leveraging next generation technologies to achieve stable clonal cell lines expressing high product titers and intensified gene to GMP timelines
During this presentation Fay will be discussing:
- Apollo™X represents an evolution from the original Apollo™ cell line development platform, accomplished with the application of next generation screening technology, enhanced media selection and technical expertise.
- Cell line development timeline reductions were achieved through the introduction of a single cloning step, whilst maintaining a high assurance of monoclonality through the use of single cell imaging and high resolution plate imaging technology.
- Rapid genetic characterization of clonal cell lines was made possible through the use of Targeted Locus Amplification (TLA) technology.
- Apollo™X is an expression system that can be used to generate stable, clonal cell lines capable of expressing both mAbs and other recombinant proteins with high titers, and which can be used in fed-batch and continuous processes
April 6, 2021, at 9:30am JST
Charles Heise, Ph.D., Senior Staff Scientist in the Bioprocessing Strategy & Development group at FUJIFILM Diosynth Biotechnologies, UK will be presenting on MaruXTM: demonstrating continuous biomanufacturing at 500 L scale operations
During this presentation, Charles will be discussing:
Clinical and commercial continuous manufacturing of biological products has taken another step forward with the successful production of monoclonal antibody from our fully disposable 500 L manufacturing scale non-GMP MaruXTM facility. Using the ApolloXTM high
biomass perfusion cell-line with commercially available upstream systems and SymphonXTM purification skids for point-of-use buffer dilution and connected, intensified batch processing we were able to process ~1 kg mAb/day into downstream.
April 8, 2021 at 9am JST
Cari Sadowski, Principal Scientist/Group Leader of the Science and Innovation Group at FUJIFILM Diosynth Biotechnologies, Texas will be presenting on The Development of a Manufacturing Process for Multiple AAV Gene Therapy Vectors
During this presentation Cari will be discussing:
- Viral based Gene Therapy (VGT) is a growing field with many projects initiating preclinical development and now advancing through both early and late phase clinical trials.
- As these new therapies move from benchtop to bedside, alongside the challenges to shorten development timelines and reduce the cost of goods (COGs), there is a need to establish efficient, robust processes and analytical methods for the cGMP manufacturing of Adeno-associated viral vectors (AAV).
- FUJIFILM Diosynth Biotechnologies’ AAV manufacturing platform addresses these needs by providing critical components, including a fully characterized HEK293 cGMP cell line which has been suspension adapted into serum free, chemically defined medium, ‘off the shelf’ multiple serotype Rep/Cap plasmids, AV Helper plasmid and a client specific gene of interest (GOI) plasmid. These key components have been fully integrated with FDB’s process and analytical development and cGMP manufacturing capabilities.
- FDB’s progress on establishing this AAV platform will be discussed in this presentation.
This conference is free to attend for the full agenda and registration please visit BPI Asia